co-presented by
ASSOCIATE SPONSORS
co-presented by
ASSOCIATE SPONSORS
The prime driver of growth is the volume visibility from contract duration, which is typically in the range of 2-5 years
Accenture’s revenue growth decelerated despite steady order inflows
Accenture earnings report flags the pockets of concern, going forward
India’s usage of coal is projected to rise by 8.4 percent in 2023, much higher than 1.4 percent growth for the world
Despite mediocre top-line growth, Mufti has managed to show impressive growth in profitability
The market grew by just 3.5 percent in November 2023. Lower price hikes and competition from generics are the main obstacles to higher growth
The domestic pharma's growth of 3.5 percent is the lowest monthly growth this year as a slowdown was seen across all key therapies
Renewables and export-oriented sectors such as chemicals, APIs, and IT figure among the eight themes for a rewarding investing journey in 2024 and beyond
Pyroxasulfone has huge market demand and, given the patent protection for the next few years, we see limited impact on PI’s growth story
India’s dependence on coal-based power rose in April-November 2023 despite muted capacity additions
Solar module prices almost halved in the past one year
Expansion plan supports growth momentum; however, valuations have turned quite high.
The company received orders worth Rs 18,298 crore so far in FY24 against its annual guidance of Rs 20,000 crore
The company should be able to close the gap in profit margins with India listed peers
Employee costs remain elevated despite a moderation in revenue growth
Demand for high-end healthcare facilities remains strong and Medanta is strategically cementing its footprint in north India.
Most global companies indicate continuing destocking pressures
The stock is up 51 percent in the last one year
Sales in October 2023 are estimated to have risen by 19 percent in top seven cities
A steady growth profile, strong regional presence, and a higher focus on radiology give the company an edge in a highly competitive industry
Complex and high value products are helping pharma companies overcome the price pressure in base generic drug business
The 11-member MC Pro Cricindex has risen by 3 percent since September while the Nifty was flat during this period
The company’s market share declined by 80 basis points in October from September 2023
The company has to rapidly grow its business volumes
While Safari is making the most of the opportunities, VIP remains in a weak spot
